| The News Journal | AstraZeneca strikes $8.5B cancer deal; disappoints on trial results The News Journal The companies will also work together to bring AstraZeneca's cancer thyroid treatment, selumetinib, to market. Jim Butkiewicz, chair of the University of Delaware's Economics Department, said the deal could give AstraZeneca an opportunity to reinvest ... AstraZeneca, Merck & Co. in $8.5-Billion Oncology CollaborationBioPharm International (press release) (blog) AZ, Merck link to develop and commercialise cancer drugsPharmaTimes AstraZeneca, Merck to collaborate on olaparib developmentHealio Newburgh Gazette all 60 news articles » |
from # All Medicine by Alexandros G. Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2tR5aGx
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00302841026182,00306932607174,alsfakia@gmail.com,